(-0.88%) 4 967.23 points
(0.56%) 37 986 points
(-2.05%) 15 282 points
(0.62%) $83.24
(0.17%) $1.760
(0.36%) $2 406.70
(1.29%) $28.75
(-1.17%) $943.30
(-0.14%) $0.938
(-0.21%) $11.02
(0.56%) $0.808
(-0.95%) $93.01
Live Chart Being Loaded With Signals
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide...
Stats | |
---|---|
Today's Volume | 6 548.00 |
Average Volume | 3 037.00 |
Market Cap | 330.77B |
EPS | €0 ( 2024-04-15 ) |
Next earnings date | ( €0 ) 2024-07-17 |
Last Dividend | €1.190 ( 2023-08-25 ) |
Next Dividend | €0 ( N/A ) |
P/E | 19.69 |
ATR14 | €0.194 (0.14%) |
Volume Correlation
Johnson & Johnson Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Johnson & Johnson Correlation - Currency/Commodity
Johnson & Johnson Financials
Annual | 2023 |
Revenue: | €85.16B |
Gross Profit: | €58.61B (68.82 %) |
EPS: | €13.88 |
Q4 | 2023 |
Revenue: | €21.40B |
Gross Profit: | €14.60B (68.23 %) |
EPS: | €-0.0300 |
Q3 | 2023 |
Revenue: | €21.35B |
Gross Profit: | €14.75B (69.06 %) |
EPS: | €10.81 |
Q2 | 2023 |
Revenue: | €25.53B |
Gross Profit: | €17.32B (67.83 %) |
EPS: | €1.980 |
Financial Reports:
No articles found.
Johnson & Johnson Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€1.130 (N/A) |
€1.130 (N/A) |
€1.130 (N/A) |
€1.190 (N/A) |
€1.190 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.415 | 2008-02-22 |
Last Dividend | €1.190 | 2023-08-25 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 65 | -- |
Total Paid Out | €56.18 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.64 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.69 | |
Div. Directional Score | 8.29 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SDF.DE | Ex Dividend Junior | 2023-05-11 | Annually | 0 | 0.00% | |
CTP2.DE | Ex Dividend Knight | 2023-10-03 | Quarterly | 0 | 0.00% | |
KSC.DE | Ex Dividend Junior | 2023-05-11 | Annually | 0 | 0.00% | |
47T.F | Ex Dividend Knight | 2023-09-06 | Annually | 0 | 0.00% | |
TOTB.DE | Ex Dividend King | 2024-01-02 | Quarterly | 0 | 0.00% | |
EKT.DE | Ex Dividend Knight | 2023-05-18 | Annually | 0 | 0.00% | |
MZX.DE | Ex Dividend Knight | 2023-06-08 | Sporadic | 0 | 0.00% | |
AIY.DE | Ex Dividend Junior | 2023-08-01 | Sporadic | 0 | 0.00% | |
WCH.DE | Ex Dividend Knight | 2023-05-18 | Annually | 0 | 0.00% | |
GKS.DE | Ex Dividend Junior | 2023-06-29 | Sporadic | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.378 | 1.500 | 2.44 | 3.66 | [0 - 0.5] |
returnOnAssetsTTM | 0.210 | 1.200 | 3.01 | 3.61 | [0 - 0.3] |
returnOnEquityTTM | 0.492 | 1.500 | 5.65 | 8.47 | [0.1 - 1] |
payoutRatioTTM | 0.335 | -1.000 | 6.65 | -6.65 | [0 - 1] |
currentRatioTTM | 1.156 | 0.800 | 9.22 | 7.38 | [1 - 3] |
quickRatioTTM | 0.914 | 0.800 | 9.33 | 7.46 | [0.8 - 2.5] |
cashRatioTTM | 0.472 | 1.500 | 8.49 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.175 | -1.500 | 7.08 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 2.89 | 1.000 | -0.0407 | -0.0407 | [3 - 30] |
operatingCashFlowPerShareTTM | 9.47 | 2.00 | 6.84 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 7.39 | 2.00 | 6.31 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.426 | -1.500 | 8.29 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.677 | 1.000 | 2.04 | 2.04 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.249 | 1.000 | 7.02 | 7.02 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.777 | 1.000 | 6.79 | 6.79 | [0.2 - 2] |
assetTurnoverTTM | 0.555 | 0.800 | 9.63 | 7.71 | [0.5 - 2] |
Total Score | 10.89 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 10.30 | 1.000 | 9.06 | 0 | [1 - 100] |
returnOnEquityTTM | 0.492 | 2.50 | 7.20 | 8.47 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 7.39 | 2.00 | 7.54 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.16 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 9.47 | 2.00 | 6.84 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.335 | 1.500 | 6.65 | -6.65 | [0 - 1] |
pegRatioTTM | -0.353 | 1.500 | -5.69 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.245 | 1.000 | 6.37 | 0 | [0.1 - 0.5] |
Total Score | 5.69 |
Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators